AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

NCT07339423 · tracked via the Priya Life Science UK tracker

Sponsor

Novo Nordisk A/S

Phase

Phase 3

Started

2026-02-24

Last updated

2026-07-09

Condition(s) studied

Obesity

Investigational drug(s) / intervention(s)

NNC0487-0111Placebo (matched to NNC0487-0111)

NNC0487-0111: NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

Placebo (matched to NNC0487-0111): Placebo matched to NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

Study summary

The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Key Inclusion Criteria: * Male or female (sex at birth). * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. * History of at least one self-reported unsuccessful dietary effort to lose body weight. Key Exclusion Criteria: * HbA1c ≥ 6.5% (48 millimole per mole \[mmol/mol\]) as measured by the central laboratory at screening. * History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records. * Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening.

Primary outcome measure(s)

Relative change in body weight — From baseline (week 0) to week 84
Measured as percentage of body weight.

Trial sites (72)

Facility	City	Region	Status
South Broward Research LLC	Miramar	Florida	Recruiting
Clinical Neuroscience Solution	Orlando	Florida	Recruiting
Hope Clin Res & Wellness	Conyers	Georgia	Recruiting
Endeavor Health	Skokie	Illinois	Recruiting
Midwest Inst For Clin Res	Indianapolis	Indiana	Recruiting
StudyMetrix Research LLC	City of Saint Peters	Missouri	Recruiting
New York Gastroenterology Associates	New York	New York	Recruiting
UNC Eastowne Medical Office	Chapel Hill	North Carolina	Recruiting
PharmQuest Life Sciences LLC	Greensboro	North Carolina	Recruiting
Accellacare and KDCILM, LLC	Wilmington	North Carolina	Recruiting
UPA Ctr Weight and Eating Dis	Philadelphia	Pennsylvania	Recruiting
Clinical Res Collaborative	Cumberland	Rhode Island	Recruiting
Medical Uni of SC Charleston	Charleston	South Carolina	Recruiting
Coastal Carolina Research Ctr	North Charleston	South Carolina	Recruiting
Hillcrest Clinical Research	Simpsonville	South Carolina	Recruiting
Amarillo Medical Specialists	Amarillo	Texas	Recruiting
Velocity Clinical Res-Dallas	Dallas	Texas	Recruiting
Care United Research, LLC	Forney	Texas	Recruiting
Washington Cntr Weight Mgmt	Arlington	Virginia	Recruiting
Health Res of Hampton Roads	Newport News	Virginia	Recruiting
Selma Medical Associates	Winchester	Virginia	Recruiting
Rainier Clin Res Ctr Inc	Renton	Washington	Recruiting
Fundación CESIM	Santa Rosa	La Pampa Province	Recruiting
Centro Medico Dra. Laura Maffei e Investigacion Clínica Apli	Buenos Aires	Argentina	Recruiting
Instituto de Investigaciones Clínicas Córdoba	Córdoba	Argentina	Recruiting
Sanatorio Esperanza	Esperanza, Santa Fe	Argentina	Recruiting
CIPADI	Godoy Cruz	Argentina	Recruiting
Instituto de Investigaciones Clinicas San Nicolás	San Nicolás	Argentina	Recruiting
Sydney Clinical Trials	Campbelltown	New South Wales	Recruiting
Sydney Cardiometabolic Centre	Liverpool	New South Wales	Recruiting
Hunter Diabetes Centre	Merewether	New South Wales	Recruiting
Heart of Australia	Chelmer	Queensland	Recruiting
HUB - Hôpital Erasme	Brussels	Belgium	Recruiting
UZA - UZ Antwerpen - Department of Endocrinology	Edegem	Belgium	Recruiting
Universitair Ziekenhuis Gent	Ghent	Belgium	Recruiting
UZ Leuven - Endocrinology	Leuven	Belgium	Recruiting
MECLINAS	Mechelen	Belgium	Recruiting
AZ Delta - Roeselare	Roeselare	Belgium	Recruiting
C-Health Partners	Calgary	Alberta	Recruiting
Ocean West Research Clinic	Surrey	British Columbia	Recruiting

+ 32 more sites — see the full list on the official registry below.

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07339423 on ClinicalTrials.gov ↗ ← All trials in the UK